| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000017917 |
| Receipt No. | R000020770 |
| Official scientific title of the study | Double-Blind, Placebo-Controlled Study for the Effect of Daily Ingestion of the Plum Extract on the Improvement of Blood Pressure and Blood Flow |
| Date of disclosure of the study information | 2015/06/16 |
| Last modified on | 2016/07/15 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Double-Blind, Placebo-Controlled Study for the Effect of Daily Ingestion of the Plum Extract on the Improvement of Blood Pressure and Blood Flow | |
| Title of the study (Brief title) | The Effect of Daily Ingestion of the Plum Extract on the improvement of Blood Pressure and Blood Flow | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | To prove the clinical usefulness of blood pressure and blood flow improvement by investigating effects from daily ingestion of plum extract for 12 weeks.
To evaluate the overall health promotion by secondarily examining effects of lipid metabolism, blood glucose, fatigue recovery and regulation of intestinal function. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase III |
| Assessment | |
| Primary outcomes | systolic pressure and diastolic pressure (hospital pressure and home pressure) , peripheral blood flow |
| Key secondary outcomes | T-Cho, HDL-Cho, LDL-Cho, TG,
fasting plasma glucose, HbA1c, hs-CRP, adiponectin, platelet aggregation, defecation frequency, VAS questionnaire |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of the plum extract pill daily for 12 weeks | |
| Interventions/Control_2 | Ingestion of the placebo pill daily for 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Subjects whose SBP is between 130mmHg and 160mmHg
2. Subjects who agree to participate in the current study with a written informed consent. |
|||
| Key exclusion criteria | 1. Subjects who are under treatment and medication for hypertension.
2. Subjects with serious cerebrovascular, cardiac, hepatic, renal, and / or gastrointestinal diseases, or affected with an infectious disease which is required to report to the authorities 3. Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 4. Subjects with unusually high and/or low blood pressure or abnormal hematological data 5. Subjects with serious anemia 6. Pre- or post-menopausal subjects having complaints of obvious physical changes 7. Subjects who are at risk of having allergic reactions to drugs or foods (especially plum) 8. Subjects regularly take medicine, functional foods and/or supplements ( peptide, acetic acid, GABA, geniposidic acid, flavonoids, sesamin, chlorella, olive leaves, garlics, dietary fiber, tomatoes, folic acid, etc.) which would affect the blood pressure. 9. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 10. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 11. Subjects who are pregnant or expected to be pregnant, or lactating during the study 12. Subjects who participate in other clinical trials within the last one month prior to the current clinical trial 13. Any other medical reasons judged by the principal investigator |
|||
| Target sample size | 52 | |||
| Research contact person | |
| Name of lead principal investigator | Prof. Jun NISHIHIRA, M.D., Ph.D. |
| Organization | Hokkaido Information University |
| Division name | Department of Medical Management and Informatics |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| TEL | 011-385-4411 |
| nishihira@do-johodai.ac.jp | |
| Public contact | |
| Name of contact person | Dir. Prof. Jun NISHIHIRA, M.D., Ph.D. |
| Organization | Hokkaido Information University |
| Division name | Center of Health Information Science |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| TEL | 011-385-4430 |
| Homepage URL | |
| nishihira@do-johodai.ac.jp | |
| Sponsor | |
| Institute | Hokkaido Information University |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | NAKANO.B.C. Co. Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道情報大学 保健センター |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020770 |